Gilead Sciences acquires Myogen for $2.5B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Gilead Sciences |
Myogen |
$2.5B buyout |
Gilead Sciences announced that it will acquire Myogen for $2.5 billion in a move designed to bolster Gilead's pulmonary program. |
|
Sigma Pharmaceuticals |
Australian Pharmaceutical Industries |
$422M buyout |
The buyout bid would create a company that controls two thirds of the Australian market. |
|
Genentech |
CGI Pharmaceuticals |
$525M development deal |
Genentech has agreed to pay CGI Pharmaceuticals $25 million up front and up to $500 million in milestones for the rights to collaborate on the development and commercialization of therapeutics for an unidentified target for the treatment of multiple cancer and autoimmune indications. |
|
Biogen Idec |
UCB |
$200M development pact |
Biogen Idec and Belgium-based UCB have signed a pact to develop UCB's CDP323, a small molecule alpha4-integrin inhibitor being developed as a treatment for multiple sclerosis. |
|
Plexxikon |
Servier |
$100M collaboration deal |
Plexxikon and France's Servier have struck a collaboration deal to discover non-peptidic renin inhibitors. |
|
Wyeth |
Biotica Technology |
$195M licensing deal |
Wyeth gains rights to Biotica's advanced drug candidates, a portfolio of additional rapamycin analogs, and the technology to discover new compounds. |
|
Takeda |
Xenon Pharmaceuticals |
$75.5 licensing deal |
Canada's Xenon Pharmaceuticals has agreed to license out the rights to its lead product for pain, XEN401, for Japan and certain Asian markets to Takeda. |
|
Roche |
Plexxikon |
$40M deal |
Roche and Plexxikon have signed a deal to develop and commercialize PLX4032, a therapy for cancer that selectively inhibits B-Raf(V600E). |
|
Pfizer |
PowderMed |
Development deal |
Pfizer has struck a deal to buy the UK's PowderMed, a company that has been developing a new generation of DNA-based vaccines. |
|
Starpharma |
Dendritic |
Acquisition |
Starpharma has struck a deal to buy all the stock of Dendritic Nanotechnologies it doesn't already own for about $7 million in Starpharma shares. |
|
Barr Pharmaceuticals |
Pliva |
Acquisition |
Barr Pharmaceuticals announced that it has acquired more than 70 percent of Pliva's stock. |
|
Valentis |
Urigen |
Merger |
Burlingame, CA-based Valentis announced that it would merge with Urigen through a stock swap. |